Cell Therapy News Volume 27.12 | Jul 6 2026

    0
    37






    2026-07-06 | CTN 27.12


    Cell Therapy News by STEMCELL Technologies
    Vol. 27.12 – 06 July, 2026
    TOP STORY

    Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy

    Scientists developed macrophage-preferential ionizable cationic lipid-assisted polymeric nanoparticles to co-deliver mRNAs encoding interferon-γ and a CAR molecule, enabling in vivo engineering of CAR-macrophages with a sustained M1-like phenotype.
    [ACS Nano]

    Abstract | Graphical Abstract
    PUBLICATIONSListed by the impact factor of the journal

    Intravesical Mesothelin-Based CAR T Cells Targeting MUC16 Effectively Control Bladder Cancer in Preclinical Models

    Investigators validated MUC16 as a clinically relevant target for bladder cancer, noting enriched expression in tumors recalcitrant to existing therapies. They engineered a second-generation mesothelin-based CAR and demonstrated robust activity across multiple cell lines and patient-derived tumor organoids.
    [Journal of Experimental Medicine]

    Full Article

    FATP2-Mediated Lipid Metabolism Enhances Chimeric Antigen Receptor T Cell Therapy Resistance in B Cell Acute Lymphoblastic Leukemia

    Through genome-wide CRISPR/Cas9 screening of CAR-sensitive TP53-wildtype and CAR-resistant TP53-mutated CD19 + B cell acute lymphoblastic leukemia (B-ALL) cell lines, researchers found the fatty acid transport protein 2 (FATP2) is a leukemia-intrinsic mechanism of CAR-T resistance in TP53-mutant B-ALL.
    [Leukemia]

    Full Article

    Linperlisib Enhances MUC1-Tn CAR T Cell Efficacy by Inhibiting EGR1/DUSP2 Axis to Prevent CAR T Cell Exhaustion

    Investigators confirmed Mucin1-Thomsen-nouvelle (MUC1-Tn) protein expression in T cell acute lymphoblastic leukemia cell lines and primary patient-derived bone marrow cells and subsequently developed MUC1-Tn-targeted CAR T cells.
    [Leukemia]

    Full Article | Graphical Abstract

    Circumventing Ewing Sarcoma Tumor Microenvironment Resistance by IL1RAP CAR-Modified TGFβ1-Imprinted Natural Killer Cells in Combination with IL-15 Agonist and Anti-GD2 Antibody

    Scientists found that anti-IL1RAP-CAR-NK cells significantly and specifically enhance NK cytotoxicity in vitro and decrease tumor growth and lung metastasis in vivo against IL1RAP+ Ewing sarcoma.
    [Journal for Immunotherapy of Cancer]

    Full Article

    CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance

    The authors evaluated the O-glycosylated IIICS domain of fibronectin as a CAR T cell target. FDC6-BBζ and 5E5-BBζ CAR T cells achieved durable tumor control with increased intratumoral CD3⁺ infiltration and reduced tumor-collagen overlap
    [Cancer Immunology Research]

    Abstract
    Learn how hematopoietic stem and progenitor cells (HSPCs) can be applied in translational clinical research and cell therapy manufacturing in this free virtual course.
    REVIEWS

    Advances and Prospects in Cell Therapy for Cancer: Explorations from T Cells to Stem Cells

    In vivo engineering technologies that directly deliver CAR genes in situ are emerging as promising approaches to lower costs and simplify manufacturing by bypassing complex ex vivo procedures.
    [Signal Transduction and Targeted Therapy]

    Full Article

    The Evolving Role of Cytokines for CAR-T Cell Manufacturing and Beyond

    The authors illustrate the evolving use of cytokines, reveal non-standardized clinical CAR-T cell manufacturing parameters, and summarize preclinical and next-generation concepts, which may improve manufacturing efficiency, cost-effectiveness and therapeutic outcomes.
    [Nature Biomedical Engineering]

    Perspective
    INDUSTRY AND POLICY NEWS

    FDA Grants Full Approval to Engineered Cell Therapy for Treating Rare Sarcoma

    The US FDA has granted full approval for the immunotherapy afamitresgene autoleucel (Tecelra®, also known as afami-cel) for the treatment of patients with  synovial sarcoma.
    [Memorial Sloan Kettering Cancer Center]

    Press Release

    FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

    The US FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia.
    [US FDA]

    Press Release
    FEATURED EVENT

    11th CAR-TCR Summit

    September 15-17, 2026
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Tumor Immunology

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Associate – Epigenomic Regulation of Metabolism

    Baylor College of Medicine – Houston, Texas, United States

    Postdoctoral Researcher – Bone Organoids

    ETH Zurich – Zurich, Switzerland

    Postdoctoral Associate – Therapeutic Applications of iPSCs

    Singapore-MIT Alliance for Research and Technology – Singapore

    Clinical Lab Scientist – Cell Therapy

    UCLA – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2